Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
945 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer(VANILLA) | terminated | Phase 3 | 546 | SanofiINDUSTRY | 24 | Jun 7, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT01440088 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | completed | Phase 3 | 640 | Threshold PharmaceuticalsINDUSTRY | 13 | Jun 2, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT01350804 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)(NURTURE 1) | completed | Phase 3 | 551 | Novartis PharmaceuticalsINDUSTRY | 15 | May 23, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT00961415 | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 376 | Hoffmann-La RocheINDUSTRY | 12 | Feb 22, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT00789828 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)(EXIST-1) | completed | Phase 3 | 117 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 3, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00879333 | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)(GRANITE-1) | completed | Phase 3 | 656 | Novartis PharmaceuticalsINDUSTRY | 22 | Nov 3, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
| NCT00373425 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors(RADIANT) | completed | Phase 3 | 1,252 | OSI PharmaceuticalsINDUSTRY | 19 | Sep 17, 2015 | clinicaltrials |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT00528567 | BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer | completed | Phase 3 | 2,591 | Hoffmann-La RocheINDUSTRY | 40 | Sep 4, 2015 | clinicaltrials |
| NCT00391092 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 16 | Aug 28, 2015 | clinicaltrials |
| NCT00440310 | Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases | completed | Phase 3 | 483 | Light Sciences OncologyINDUSTRY | 13 | Aug 25, 2015 | clinicaltrials |
| NCT01014208 | Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma(ORCHARRD) | completed | Phase 3 | 447 | GlaxoSmithKlineINDUSTRY | 26 | Aug 7, 2015 | clinicaltrials |
| NCT00044291 | Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | completed | Phase 3 | 865 | Intarcia TherapeuticsINDUSTRY | 4 | Jul 31, 2015 | clinicaltrials |
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia(TEAM-ET) | completed | Phase 3 | 106 | AOP Orphan Pharmaceuticals AGINDUSTRY | 5 | Jul 29, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT00448591 | A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer. | completed | Phase 3 | 2,296 | Hoffmann-La RocheINDUSTRY | 36 | May 25, 2015 | clinicaltrials |
| NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 580 | GlaxoSmithKlineINDUSTRY | 25 | May 6, 2015 | clinicaltrials |
| NCT01519700 | Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim(PIONEER) | completed | Phase 3 | 218 | SandozINDUSTRY | 6 | May 6, 2015 | clinicaltrials |
| NCT02423837 | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma(BRiF) | unknown | Phase 3 | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 22, 2015 | clinicaltrials |
| NCT01203228 | Dose-reduced Versus Standard Conditioning in MDS/sAML(RICMAC) | terminated | Phase 3 | 129 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00215683 | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | completed | Phase 2 / Phase 3 | 137 | Ferring PharmaceuticalsINDUSTRY | 7 | Apr 1, 2015 | clinicaltrials |
| NCT00457691 | Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 768 | PfizerINDUSTRY | 34 | Mar 30, 2015 | clinicaltrials |
| NCT00065325 | The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer(EFECT) | completed | Phase 3 | 694 | AstraZenecaINDUSTRY | 15 | Feb 24, 2015 | clinicaltrials |
| NCT00556322 | A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 27 | Feb 23, 2015 | clinicaltrials |
| NCT00556712 | A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 889 | Hoffmann-La RocheINDUSTRY | 28 | Feb 11, 2015 | clinicaltrials |
| NCT00863746 | A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).(MISSION) | completed | Phase 3 | 703 | BayerINDUSTRY | 34 | Jan 19, 2015 | clinicaltrials |
| NCT01339260 | An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting | completed | Phase 3 | 1,455 | Helsinn Healthcare SAINDUSTRY | 15 | Nov 26, 2014 | clinicaltrials |
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma(SAPPHIRE) | terminated | Phase 3 | 27 | Isarna Therapeutics GmbHINDUSTRY | 16 | Nov 14, 2014 | clinicaltrials |
| NCT01041404 | ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer | completed | Phase 3 | 584 | Hoffmann-La RocheINDUSTRY | 24 | Nov 5, 2014 | clinicaltrials |
| NCT01166542 | Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers | completed | Phase 3 | 167 | Oncolytics BiotechINDUSTRY | 13 | Nov 5, 2014 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials